CWC Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$719K Sell
5,630
-61
-1% -$7.62K 0.34% 70
2025
Q4
$694K Sell
5,691
-16
-0.3% -$1.83K 0.34% 70
2025
Q3
$572K Buy
5,707
+157
+3% +$14.1K 0.28% 82
2025
Q2
$460K Buy
5,550
+183
+3% +$14.6K 0.24% 88
2025
Q1
$435K Buy
5,367
+1,919
+56% +$172K 0.25% 86
2024
Q4
$311K Buy
3,448
+67
+2% +$6.49K 0.31% 87
2024
Q3
$334K Buy
+3,381
New +$332K 0.33% 82

Other funds holding XBI

CWC Advisors's XBI Position: Q1 2026 in Review

CWC Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.1% in Q1 2026, selling an estimated $7.62K and leaving 5,630 shares worth $719K. The position accounts for 0.34% of the portfolio, ranked #70.

CWC Advisors first reported a position in XBI in Q3 2024 and has held it in 7 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • CWC Advisors held 5,630 shares of State Street SPDR S&P Biotech ETF worth $719K as of Q1 2026.
  • CWC Advisors sold 61 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $7.62K.
  • State Street SPDR S&P Biotech ETF made up 0.34% of CWC Advisors's portfolio in Q1 2026, its #70 holding.
  • CWC Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 7 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on CWC Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.